TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11589718
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic plus Thiazide diuretic (LD plus TD)
Study: 9716148
Drug: routine detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine detection of LA antibodies
Study: 7983959
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (n = 114)
Study: 970902
Drug: Furosemide prophylaxis
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide prophylaxis (20-60 mg) in LPG
Study: 28369381
Drug: Maraviroc 300
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg twice daily
Study: 8464952
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DMI
Study: 8464952
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DMI
Study: 3511767
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine 0.3 mg
Study: 22254076
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 µg/day
Study: 25292137
Drug: D-dimer >
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer > 0.987 mcg/ml and swelling > 1.5 cm of shin
Study: 22378727
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol (PS) supplementation (1.6 g daily for 4 weeks)
Study: 17505700
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (15 microg ethinyl estradiol/60 microg gestodene)
Study: 11932759
Drug: 8-month regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-month regimen of anti-tuberculous drugs (NTCP recommended)
Study: 11932759
Drug: 6-month regimen
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month regimen of anti-tuberculous drugs
Study: 9617982
Drug: Sibutramine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 30 mg
Study: 9617982
Drug: Dextroamphetamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (both doses)
Study: 30293457
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional exercise therapy)
Study: 23008177
Drug: PCI using
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI using bare metal or drug-eluting stents (control arm)
Study: 16733496
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg/day (group A)
Study: 16733496
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 10 mg/day (group B)
Study: 11379400
Drug: Epoetin alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alpha (10,000 U subcutaneously, thrice weekly)
Study: 7955813
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg felbamate twice a day
Study: 7955813
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg felbamate twice a day
Study: 7955813
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of felbamate (600 mg and 1200 mg)
Study: 3653463
Drug: Tolerance of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerance of treatments
Study: 25675558
Drug: Medication (nimodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (nimodipine and fluoxetine)
Study: 23754711
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day for 6 weeks
Study: 11037003
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (ginkgo) 240 mg/day or 160 mg/day
Study: 19501439
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa to increase hemoglobin levels to 13 g/dL
Study: 10232440
Drug: Bronchial provocation
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial provocation with lysine-aspirin
Study: 10172710
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 1500 to 2000 micrograms via pressurized metered-dose inhaler with spacer
Study: 6088252
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg)
Study: 25286913
Drug: Hemodynamically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodynamically guided HF management using daily uploaded pressures
Study: 22311517
Drug: PTH(1‐34) infusion
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1‐34) infusion
Study: 20835586
Drug: Multiple-dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose inhaler (400 µg of MF once a day for 60 days)
Study: 20835586
Drug: Single-dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose inhaler (400 µg of MF once a day for 60 days)
Study: 16076379
Drug: Sevelamer 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 6.0 g/day (Group A)
Study: 16076379
Drug: Sevelamer 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 3.0 g/day and Calcium Carbonate 3.0 g/day (Group B)
Study: 16076379
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate 3.0 g/day (Group C)
Study: 19401423
Drug: Rosiglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone treatment
Study: 10450630
Drug: Full Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full Cognitive Therapy (FCT)
Study: 10450630
Drug: Brief Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive Therapy (BCT)
Study: 17719303
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride plus oral NAC (600 mg bid)
Study: 15212623
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 1000 mg/day
Study: 15212623
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2000 mg/day
Study: 15212623
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2000 mg
Study: 11456285
Drug: Glycine 5
Normalized name: glycine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine 5 g orally
Study: 3044870
Drug: Flurbiprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (300 mg: 100 mg twice a day orally and 100 mg suppository at night)
Study: 3044870
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg: 25 mg twice daily orally and 25 mg suppository at night)
Study: 29488900
Drug: Sublingual nitroglycerine
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerine (0.4 mg)
Study: 21951683
Drug: Autologous peripheral
Normalized name: Autologous peripheral blood-derived CD34+ cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous peripheral blood stem cell transplantation (ASCT) after high-dose cyclophosphamide and busulfan
Study: 21951683
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy with etoposide and mitoxantrone
Study: 8705395
Drug: rBPI23 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI23 administered as a 5 or 30 min infusion at doses of 0.1 to 1 mg/kg
Study: 1510645
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg, twice daily)
Study: 30415354
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg capsule orally before RYGB surgery
Study: 30415354
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg capsule orally 2 months after RYGB surgery
Study: 30415354
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg capsule orally before and after RYGB surgery
Study: 2507265
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus placebo
Study: 1954640
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle cream)
Study: 22520141
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (PRV), RotaTeq(®), 3 doses at approximately 6, 10, and 14 weeks of age
Study: 20080470
Drug: Intensive use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive use of lotion containing 3% urea, polidocanol, and hyaluronic acid
Study: 20080470
Drug: Standard use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard use of lotion containing 3% urea, polidocanol, and hyaluronic acid
Study: 10981168
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers
Study: 18595261
Drug: Long‐acting calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long‐acting calcium antagonists
Study: 15751264
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone therapy (estrogen-progestin)
Study: 15751264
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment arms of the WHI (not specified)
Study: 1087732
Drug: Intravenous L-5-hydroxytryptophan
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-5-hydroxytryptophan (L-5HTP)
Study: 27091535
Drug: Guided Internet‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet‐based cognitive behavioral therapy for insomnia (ICBT‐i)
Study: 27091535
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control treatment (ICBT‐ctrl)
Study: 15794787
Drug: Oral desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral desmopressin 400 microg
Study: 8784652
Drug: Zalospirone 45
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalospirone 45 mg/day
Study: 8784652
Drug: Zalospirone 6
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalospirone 6 mg/day
Study: 8784652
Drug: Zalospirone 15
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalospirone 15 mg/day
Study: 6467858
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (50 mg/day) combined with 25-50 micrograms of 25 OH cholecalciferol (calcifediol) per day for 6-18 months (12 patients) and 31-58 months (9 patients)
Study: 24112635
Drug: Intravitreal 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 0.5 mg ranibizumab
Study: 22834417
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) gel 1.5 mg and oral micronized progesterone (P) 200 mg/day for the last 14 days of each cycle
Study: 22834417
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE) 0.625 mg and oral medroxyprogesterone acetate (MPA) 5 mg for the last 14 days of each cycle
Study: 16099600
Drug: Balsalazide (2250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide (2250 mg, twice daily for 5 days before RT and 2 weeks after completion)
Study: 16099600
Drug: Placebo (identical-appearing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-appearing, twice daily for 5 days before RT and 2 weeks after completion)
Study: 10872898
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g/day)
Study: 10545746
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplement (100 mg orally daily) in addition to RRT
Study: 3615572
Drug: Zuclopenthixol (37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuclopenthixol (37 mg daily)
Study: 3615572
Drug: Perphenazine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (30 mg daily)
Study: 23734840
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mesalazine suppository once daily for 4 weeks
Study: 23734840
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository once daily for 4 weeks
Study: 23734840
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mesalazine suppository
Study: 18420315
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal conjugate vaccine with protein D of Haemophilus influenzae as a carrier (PncPD11)
Study: 18420315
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PncCRM7)
Study: 12017793
Drug: Dentin bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentin bonding agent alone
Study: 12017793
Drug: Dentin bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentin bonding agent in combination with flowable composite
Study: 7678686
Drug: Cibenzoline (130-390
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (130-390 mg/day)
Study: 7678686
Drug: Sotalol (160-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (160-320 mg/day)
Study: 11838820
Drug: Placebo (placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo-controlled discontinuation study)
Study: 27461787
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (4.0 mL buccal infiltration)
Study: 27461787
Drug: Bupivacaine (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (4.0 mL buccal infiltration)
Study: 22549509
Drug: 930 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 930 mg/d choline intake
Study: 22549509
Drug: 480 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg/d choline intake
Study: 17683643
Drug: Litebook LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litebook LED treatment device (1,350 lux white light, spectral peaks at 464 nm and 564 nm) for 30 minutes a day upon awakening and prior to 8 A.M.
Study: 17683643
Drug: Litebook LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litebook LED treatment device
Study: 11926786
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sildenafil plus inhaled iloprost
Study: 11926786
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of sildenafil plus inhaled iloprost
Study: 9855514
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sildenafil
Study: 11926786
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of sildenafil
Study: 11926786
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sildenafil plus iloprost
Study: 9788422
Drug: NSAID (Voltaren
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (Voltaren resinat 2 x 75 mg/day for 2 weeks)
Study: 7649965
Drug: Involvement in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement in drug research
Study: 15228261
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Study: 15228261
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Study: 15228261
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Study: 15228261
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Study: 15228261
Drug: Alum-precipitated ALM
Normalized name: Precipitated Sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-precipitated ALM + BCG vaccine mixture
Study: 9074719
Drug: Heparin (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1,250 IU x 2/SC/day for 30 days)
Study: 6350097
Drug: Cimetidine, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 1200 mg daily
Study: 6350097
Drug: Antacid (Mylanta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Mylanta II, 7 oz daily)
Study: 30822490
Drug: Immediate periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate periodontal treatment (full‐mouth non‐surgical scaling and root planing, systemic antibiotics, and oral hygiene instructions)
Study: 30822490
Drug: Delayed periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed periodontal treatment (full‐mouth non‐surgical scaling and root planing, systemic antibiotics, and oral hygiene instructions)
Study: 30822490
Drug: Immediate periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate periodontal treatment
Study: 21160466
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches combined with paired associative stimulation (PAS)
Study: 21160466
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches combined with transcranial direct current stimulation (tDCS)
Study: 21160466
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches combined with paired associative stimulation (PAS)
Study: 21160466
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches combined with transcranial direct current stimulation (tDCS)
Study: 19383242
Drug: Enteric-coated diclofenac
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteric-coated diclofenac 50 mg, administered orally three times daily for 2 weeks prior to surgery
Study: 19383242
Drug: Rofecoxib 12.5
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 12.5 mg, administered orally three times daily for 2 weeks prior to surgery
Study: 19383242
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally three times daily for 2 weeks prior to surgery
Study: 9573535
Drug: Lowest tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest tertile (UProt < 1.9 g/24 hr)
Study: 9573535
Drug: Middle tertile
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle tertile (UProt 2.0 to 3.8 g/24 hr)
Study: 9573535
Drug: Highest tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest tertile (UProt 3.9 to 18.8 g/24 hr)
Study: 8159037
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg thrice daily plus dipyridamole 75 mg thrice daily
Study: 3121710
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (rt‐PA) 80 mg over 3 h
Study: 26343601
Drug: Blonanserin (8-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin (8-24 mg/day)
Study: 24302188
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray (FNS) with amoxicillin, one puff twice daily for 14 days
Study: 24302188
Drug: Amoxicillin 80
Normalized name: amoxicillin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 80 to 100 mg/kg/day for 14 days
Study: 24302188
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray (FNS) with amoxicillin
Study: 17492413
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection followed by early intravesical application of a chemotherapeutic agent
Study: 17492413
Drug: Organ-sparing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ-sparing treatment due to combined therapeutic concepts
Study: 15536108
Drug: Amlodipine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, 10 mg